Metabolic Syndrome: An Evolving Clinical Construct

Progress in Cardiovascular Diseases

Volumn 59, Issue 2, 2016, Pages 172-177

  Vassallo, Patricia ^a   Driver, Steven L ^a   Stone, Neil J ^a  

^a NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Behavioral intervention; Lifestyle; Metabolic syndrome; Technology

Indexed keywords

STATIN (PROTEIN);

ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CORONARY ARTERY ATHEROSCLEROSIS; COUNSELING; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MOTIVATION; NUTRITION; PATIENT ATTITUDE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEDENTARY LIFESTYLE; SELF MONITORING; STRESS; WAIST CIRCUMFERENCE; CARDIOVASCULAR DISEASES; HEALTH PROMOTION; HEALTHY LIFESTYLE; INVENTION; METABOLISM; ORGANIZATION AND MANAGEMENT; PROCEDURES; PSYCHOLOGY; RISK REDUCTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HEALTH PROMOTION; HEALTHY LIFESTYLE; HUMANS; INVENTIONS; METABOLIC SYNDROME X; RISK REDUCTION BEHAVIOR;

EID: 84995559847     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2016.07.012     Document Type: Review

References (50)

1. 1. Alberti, KG, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation 120:16 (2009), 1640–1645.
2. 2. Grundy, SM, Overnutrition, ectopic lipid and the metabolic syndrome. J Investig Med, 2016.
3. 3. de Ferranti, SD, et al. Prevalence of the metabolic syndrome in American adolescents: findings from the third national health and nutrition examination survey. Circulation 110:16 (2004), 2494–2497.
4. 4. Barber, TM, et al. Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance. Clin Med 16:3 (2016), 262–266.
5. 5. Reaven, GM, Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:12 (1988), 1595–1607.
6. 6. Expert Panel on Detection, E. and A. Treatment of High Blood Cholesterol in, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:19 (2001), 2486–2497.
7. 7. Wildman, RP, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 168:15 (2008), 1617–1624.
8. 8. Dhana, K, et al. Metabolically healthy obesity and the risk of cardiovascular disease in the elderly population. PLoS One, 11(4), 2016, e0154273.
9. 9. Keramati, AR, et al. A form of the metabolic syndrome associated with mutations in DYRK1B. N Engl J Med 370:20 (2014), 1909–1919.
10. 10. Hu, G, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164:10 (2004), 1066–1076.
11. 11. Marchesini, G, Marzocchi, R, Metabolic syndrome and NASH. Clin Liver Dis 11:1 (2007), 105–117 [ix].
12. 12. Watanabe, H, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 117:10 (2008), 1255–1260.
13. 13. Lakka, HM, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:21 (2002), 2709–2716.
14. 14. Ford, ES, The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the national health and nutrition examination survey II mortality study. Atherosclerosis 173:2 (2004), 309–314.
15. 15. Iribarren, C, et al. Metabolic syndrome and early-onset coronary artery disease: is the whole greater than its parts?. J Am Coll Cardiol 48:9 (2006), 1800–1807.
16. 16. Appel, LJ, et al. Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med 365:21 (2011), 1959–1968.
17. 17. Robinson, JG, Stone, NJ, Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am J Cardiol 98:10 (2006), 1405–1408.
18. 18. Echahidi, N, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation 116:11 Suppl. (2007), I213–I219.
19. 19. Pathak, RK, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: along-term follow-up study (LEGACY). J Am Coll Cardiol 65:20 (2015), 2159–2169.
20. 20. Pathak, RK, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 64:21 (2014), 2222–2231.
21. 21. Flegal, KM, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 307:5 (2012), 491–497.
22. 22. Bradshaw, PT, Monda, KL, Stevens, J, Metabolic syndrome in healthy obese, overweight, and normal weight individuals: the atherosclerosis risk in communities study. Obesity (Silver Spring) 21:1 (2013), 203–209.
23. 23. Defronzo, RA, et al. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care 36:11 (2013), 3607–3612.
24. 24. Gerstein, HC, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 78:3 (2007), 305–312.
25. 25. McLaughlin, T, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139:10 (2003), 802–809.
26. 26. Flowers, E, et al. Use of plasma triglyceride/high-density lipoprotein cholesterol ratio to identify increased cardio-metabolic risk in young, healthy south Asians. Indian J Med Res 141:1 (2015), 68–74.
27. 27. Ridker, PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:21 (2008), 2195–2207.
28. 28. Ridker, PM, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380:9841 (2012), 565–571.
29. 29. Yusuf, S, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374:21 (2016), 2021–2031.
30. 30. Waters, DD, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 61:2 (2013), 148–152.
31. 31. Ong, KL, et al. Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study). Am J Cardiol 113:10 (2014), 1593–1598.
32. 32. Lehr, A, SL, D, NJ, S, The ABCDs of lifestyle counseling. JAMA Card 1 (2016), E1–E2.
33. 33. Sacks, FM, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 360:9 (2009), 859–873.
34. 34. Dansinger, ML, et al. Comparison of the Atkins, Ornish, weight watchers, and zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 293:1 (2005), 43–53.
35. 35. Jacobs, DR Jr., et al. Association of 1-y changes in diet pattern with cardiovascular disease risk factors and adipokines: results from the 1-y randomized Oslo diet and exercise study. Am J Clin Nutr 89:2 (2009), 509–517.
36. 36. Bo, S, et al. Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. J Gen Intern Med 22:12 (2007), 1695–1703.
37. 37. Chirinos, DA, et al. Lifestyle modification and weight reduction among low-income patients with the metabolic syndrome: the CHARMS randomized controlled trial. J Behav Med 39:3 (2016), 483–492.
38. 38. Ma, J, et al. Translating the diabetes prevention program lifestyle intervention for weight loss into primary care: a randomized trial. JAMA Intern Med 173:2 (2013), 113–121.
39. 39. Gomez-Pardo, E, et al. A comprehensive lifestyle peer group-based intervention on cardiovascular risk factors: the randomized controlled fifty-fifty program. J Am Coll Cardiol 67:5 (2016), 476–485.
40. 40. Van Name, MA, et al. Effective translation of an intensive lifestyle intervention for Hispanic women with Prediabetes in a community health center setting. Diabetes Care, 2016.
41. 41. Kukkonen-Harjula, KT, et al. Effects of a weight maintenance program with or without exercise on the metabolic syndrome: a randomized trial in obese men. Prev Med 41:3–4 (2005), 784–790.
42. 42. Kemmler, W, et al. Exercise decreases the risk of metabolic syndrome in elderly females. Med Sci Sports Exerc 41:2 (2009), 297–305.
43. 43. Thomas, TR, et al. Exercise and the metabolic syndrome with weight regain. J Appl Physiol 109:1 (2010), 3–10.
44. 44. Ganesan, AN, et al. International mobile-health intervention on physical activity, sitting, and weight: the Stepathlon cardiovascular health study. J Am Coll Cardiol 67:21 (2016), 2453–2463.
45. 45. Spring, B, et al. Multiple behavior changes in diet and activity: a randomized controlled trial using mobile technology. Arch Intern Med 172:10 (2012), 789–796.
46. 46. Knowler, WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:6 (2002), 393–403.
47. 47. The Diabetes Prevention Program, Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:4 (1999), 623–634.
48. 48. Bassi, N, et al. Lifestyle modification for metabolic syndrome: a systematic review. Am J Med, 127(12), 2014, 1242 [e1–10].
49. 49. Spring, B, et al. Integrating technology into standard weight loss treatment: a randomized controlled trial. JAMA Intern Med 173:2 (2013), 105–111.
50. 50. Martin, SS, et al. mActive: arandomized clinical trial of an automated mHealth intervention for physical activity promotion. J Am Heart Assoc, 4, 2015, 11.